Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · IEX Real-Time Price · USD
0.930
+0.070 (8.14%)
Jul 22, 2024, 10:03 AM EDT - Market open
Tiziana Life Sciences Employees
Tiziana Life Sciences had 9 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,965,667
Market Cap
89.68M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Alpha Teknova | 211 |
CASI Pharmaceuticals | 176 |
Hyperfine | 131 |
AlloVir | 112 |
HilleVax | 90 |
InflaRx | 62 |
BeyondSpring | 36 |
Clearside Biomedical | 30 |
TLSA News
- 23 days ago - Tiziana Receives $3.4 Million in Non-Dilutive Funding - GlobeNewsWire
- 26 days ago - Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab - GlobeNewsWire
- 7 weeks ago - Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today® - GlobeNewsWire